ReviewGene therapy2011
Progress and prospects: hurdles to cardiovascular gene therapy clinical trials.
Review in Gene therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026Review
- Characterization of Inflammation in In Vivo Mouse Myocardium Using Longitudinal Rotating Frame Relaxation Time (TNMR in biomedicine · 2026Article
- Gene Therapy: An Historical Overview for Familial Hearing Loss.International journal of molecular sciences · 2025Review
- Progress in Clinical Gene Therapy for Cardiac Disorders.Molecular diagnosis & therapy · 2023Review
- Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments.Cells · 2021Review
- Novel Cell-Based and Tissue Engineering Approaches for Induction of Angiogenesis as an Alternative Therapy for Diabetic Retinopathy.International journal of molecular sciences · 2020Review
- Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Angiogenic gene therapy in cardiovascular diseases: dream or vision?European heart journal · 2017Review
- A short discourse on vascular tissue engineering.NPJ Regenerative medicine · 2017Article
- Parallel Force/Position Control of an Epicardial Parallel Wire Robot.IEEE robotics and automation letters · 2016Article
- Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart.Gene therapy · 2016Article
- Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.Cardiovascular research · 2015Review
- Inducing gene expression by targeting promoter sequences using small activating RNAs.Journal of biological methods · 2015Article
- Toward hybrid force/position control for the Cerberus epicardial robot.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2015Article
- A New Gene Therapy Approach for Cardiovascular Disease by Non-coding RNAs Acting in the Nucleus.Molecular therapy. Nucleic acids · 2014Review
- The Use of Gene Therapy for Ablation of Atrial Fibrillation.Arrhythmia & electrophysiology review · 2014Article
- The road ahead: working towards effective clinical translation of myocardial gene therapies.Therapeutic delivery · 2014Review
- A parallel wire robot for epicardial interventions.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2014Article
- MicroRNA based treatment of cardiomyopathy: not all dystrophies are created equal.Journal of the American Heart Association · 2013Article
- Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice.Journal of the American Heart Association · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several gene therapy approaches have been designed for the treatment of cardiovascular diseases. A positive finding is that the safety of cardiovascular gene therapy has been excellent even in long-term follow-up. However, several hurdles to this field are still present. A major disappointing feature of the trials is that while preclinical and uncontrolled phase-I gene therapy trials have been positive, none of the randomized controlled phase-II/III cardiovascular gene therapy trials have shown clinically relevant positive effects. Low gene transfer efficiency seems to be associated with several trials. A sophisticated efficient delivery method for cardiovascular applications is still lacking and only low concentrations of the gene product are produced in the target tissues. Only a few gene therapy vectors can be produced in large scale. In addition, inflammatory reactions against vectors and inability to regulate gene expression are still present. Furthermore, a strong placebo effect is affecting the results in gene therapy trials, and long-term trials have become more difficult to conduct because of the multiplicity of therapies applied simultaneously on the patients. This review summarizes advances and obstacles of current cardiovascular clinical gene therapy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.